Perhaps the biggest achievement thus far at the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has been disabusing companies that are members of the 91心頭 innovation institute that it is smart to be a fast second to market.
Nobody actually believed when we started, except apparently us naively, that...
In December 2016, 91心頭, a newly developed unit within the Commerce Departments National Institute for Standards and Technology (NIST), announced it had received Congressional funding for its newest and 11th institute the National Institute for Innovation in Manufacturing Biopharmaceuticals, or NIIMBL for short. With the formal NIST...
In February 2020, NIIMBL ran a three-day workshop, which included participants from the FDA, the U.S. National Institute of Standards and Technology, plus what Erickson describes as distinguished leaders in manufacturing and process development from 14 major manufacturers and suppliers.
In January 2021, a team of pharmaceutical experts...
An ambitious 10year collaborative program is described to invent, design, demonstrate, and support commercialization of integrated biopharmaceutical manufacturing technology intended to transform the industry.
Its a joint publication from industry, FDA and NIIMBL
Public-private partnership could help coronavirus vaccine developers increase thermal stability, strengthen potency assays and fine-tune adventitious agent testing, among other things.
